Oct. 27, 2009 (Hugin AS) --
Leiden, The Netherlands (October 27, 2009) - Dutch biopharmaceutical
company Crucell (NASDAQ:CRXL) N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX)
today announced that it will release its financial results for the
third quarter 2009 on Tuesday November 3, 2009 at 07:45 Central
European Time (CET).
At 14:00 Central European Time (CET), Crucell's management will
conduct a conference call, which will also be webcast. To participate
in the conference call, please call one of the following telephone
numbers 15 minutes prior to the event:
+44 203 003 2666 for the UK;
+1 646 843 4608 for the US; and
+3120 794 8426 for the Netherlands
Following a presentation of the results, the lines will be opened for
a question and answer session.
The live audio webcast can be accessed via the homepage of Crucell's
website at www.crucell.com and will be archived and available for
replay following the event.
About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a
global biopharmaceutical company focused on research development,
production and marketing of vaccines, proteins and antibodies that
prevent and/or treat infectious diseases. Its vaccines are sold in
public and private markets worldwide. Crucell's core portfolio
includes a vaccine against hepatitis B, a fully-liquid vaccine
against five important childhood diseases and a virosome-adjuvanted
vaccine against influenza. Crucell also markets travel vaccines, such
as the only oral anti-typhoid vaccine, an oral cholera vaccine and
the only aluminum-free hepatitis A vaccine on the market. The Company
has a broad development pipeline, with several product candidates
based on its unique PER.C6® production technology. The Company
licenses its PER.C6® technology and other technologies to the
biopharmaceutical industry. Important partners and licensees include
DSM Biologics, Sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck &
Co. Crucell is headquartered in Leiden, the Netherlands, with
subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the USA.
The Company employs over 1000 people. For more information, please
visit www.crucell.com.
Forward-looking statements
This press release contains forward-looking statements that involve
inherent risks and uncertainties. We have identified certain
important factors that may cause actual results to differ materially
from those contained in such forward-looking statements. For
information relating to these factors please refer to our Form 20-F,
as filed with the U.S. Securities and Exchange Commission on April
22, 2009, in the section entitled 'Risk Factors'. The Company
prepares its financial statements under International Financial
Reporting Standards (IFRS).
Financial Calendar
9 February 2010 Q4 Results 2009
11 May 2010 Q1 Results 2010
4 June 2010 Annual General Meeting of Shareholders
17 August 2010 Q2 Results 2010
9 November 2010 Q3 Results 2010
15 February 2011 Q4 Results 2010
For further information please contact:
Crucell N.V.
Oya Yavuz
Vice President
Corporate Communications & Investor Relations
Tel. +31-(0)71-519 7064
ir@crucell.com
www.crucell.com
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
http://hugin.info/132631/R/1350345/325785.pdf
